LON:ETX e-therapeutics (ETX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About e-therapeutics Stock (LON:ETX) Get e-therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.52 million shsAverage Volume758,869 shsMarket Capitalization£52.59 millionP/E RatioN/ADividend Yield3.35%Price TargetN/AConsensus RatingN/A Company Overview e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom. Read More Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETX Stock News Headlinese-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OSOctober 1, 2025 | markets.businessinsider.come-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 ...July 11, 2025 | morningstar.comMFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. | Porter & Company (Ad)e-therapeutics plc: e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical DataJuly 10, 2025 | finanznachrichten.dee-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finanznachrichten.dee-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finance.yahoo.comEnsem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636April 22, 2025 | tmcnet.comElicio Therapeutics stock slides on $10M securities offeringJanuary 30, 2025 | msn.comSee More Headlines ETX Stock Analysis - Frequently Asked Questions How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) posted its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.03. How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings3/17/2020Today5/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees35Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.07 Book ValueGBX 5 per share Price / BookN/AMiscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£52.59 million OptionableNot Optionable Beta0.46 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (LON:ETX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
